The LC-MS/MS analyses of CAP-treated tumours revealed that the highest DFCR concentrations was 511 μM, within the range tested in this competition assay, supporting that the observed decrease in CDA activity in CAP-treated tumours was not related to a substrate competition. This evidence concerns the gene CDA and neoplasm.